Of 142 respondents, 53% supported, 10% were uncertain, and 37% opposed legalizing euthanasia for terminal illness with severe symptoms. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Cerebral small vessel disease (cSVD) is a major cause of vascular dementia and stroke. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dietary intake moderated the association between several cSVD biomarkers and MoCA scores such that the expected negative association between cSVD biomarkers and cognition was seen at low levels of healthy dietary intake, but not at medium or high levels. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
< 0.0036), the MCRS group exhibited significantly worse performance on word list memory, word list recall, and MMSE-KC compared to the MCI group without slow gait. 2 key findings →
Participants: 81 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Informal caregivers often seek additional support. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In this update, we examine a checklist for real-world evidence use in Medicare drug price negotiations under the Inflation Reduction Act, a review of health technology assessment reassessments across major health technology assessment agencies, and two complementary studies that used natural experiment approaches to explore the relationship between herpes zoster vaccination and reduced dementia risk. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In 2024, 90% of Medicare Advantage (MA) enrollees were in a plan that required prior authorization of home health care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We identified 11,480 beneficiaries in the IDEAS study sample and 3,008,067 in the eligible sample. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In highly segregated counties, Black older adults with elevated CVD demonstrated worse memory than those with lower CVD; in less segregated counties, memory levels did not differ by CVD. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
All non-differential bias scenarios were biased toward the null (Table 1). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The development of more effective disease-modifying treatments for Alzheimer's disease (AD) is compromised by the lack of streamlined measures to detect and monitor the full spectrum of neurodegeneration, including white matter pathology, which begins early. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study aimed to investigate the bidirectional causal relationship between celiac disease (CD) and the risk of Alzheimer disease (AD) or frontotemporal dementia (FTD) using Mendelian randomization (MR), in order to clarify prior inconsistent findings. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Eight proteins were differently expressed in carriers with larger WMH volumes (Figure 1). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The IVW analysis indicated that antithrombotic agents (odds ratio [OR] = 2.12, 95% confidence interval [CI] = 1.03-4.34, p = 0.04), HMG CoA reductase inhibitors (OR = 1.36, 95% CI = 1.07-1.72, p = 0.01), and salicylic acid and derivatives (OR = 2.77, 95% CI = 1.44-5.32, p = 0.002) are a strong risk factor for dementia with Lewy bodies (DLB); diuretics (OR = 1.13, 95% CI = 1-1.27, p = 0.047) and calcium channel blockers (OR = 1.16, 95% CI = 1.04-1.29, p = 0.007) might be a risk factor for vascular dementia; thyroid preparations (OR = 1.03, 95% CI = 1.01-1.06, p = 0.01), diuretics (OR = 1.06, 95% CI = 1.02-1.11, p = 0.004), and immunosuppressants (OR = 1.07, 95% CI = 1.01-1.12, p = 0.001), are a risk factor for frontotemporal dementia; HMG CoA reductase inhibitors is a risk factor for dementia in Alzheimer disease (OR = 1.32, 95% CI = 1.05-1.65, p = 0.01). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
34/100
This study examines the accuracy of CTseg segmentation software to diagnose Alzheimer's disease dementia and other dementias using routine CT scans from a New Zealand memory service. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sex was not a predictor of the total scores of MoCA. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global increase in dementia cases, which is predicted to exceed 152 million by 2050, poses substantial challenges to healthcare systems and caregiving structures. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a neurodegenerative disorder characterized by a significant decline in cognitive function. 4 key findings →
Participants: 65 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The results indicated good usability for the MoCA Duo. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mean activity from actigraphy did not differ within dyad members. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
• Understudied Native Hawaiian and Pacific Islander populations in Alzheimer's Disease and Related Dementia. • Risk and resiliency factors in Alzheimer's Disease and Related Dementia for American Samoa adults. • Using the Kimberley Indigenous Cognitive Assessment tool to determine ADRD potentially modifiable risk and protective factors. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The mean age of the cohort was 77.4 ± 6.8 years, with 62% males and nearly equal urban–rural distribution. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The accuracy of α-synuclein-SAA for DLB was 87% (95% confidence interval [CI]: 77% to 98%) in CSF, 85% (95% CI: 75% to 98%) in skin, 58% (95% CI: 47% to 69%) in olfactory mucosa, and 59% (95% CI: 51% to 66%) in urine. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
• AT use was limited and AT type used varied by caregiver living arrangement. • Most used ATs: daily living support and risk prevention; risk response least used. • Daily living support ATs linked to fewer care hours. • Risk prevention ATs tied to longer PT, higher CarerQol-7D, and lower SRB scores. • Daily support and risk response ATs most likely to extend PT by over six months. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Thirty-one articles were included. This conceptual analysis revealed the evolution of in-home respite care service content over time and summarized three key attributes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events